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(19/48) and 39.6% (19/48), respectively, although there was no CYPs 
positive cases in 30 squamous cell carcinomas. The CYPs positive rates 
in female adenocarcinoma were higher than those in male adenocarci-
noma. The CYPs positive rates in early adenocarcinoma were higher 
than those in advanced adenocarcinoma. The CYPs positive rates in 
well and moderately differentiated adenocarcinoma were higher than 
those in poorly differentiated adenocarcinoma. There were positive 
relationships among CYP1A1, CYP2E1 and Cyp3A expressions in ad-
enocarcinoma. The CYPs expression in adenocarcinoma was indepen-
dent of tumor p53 alterations.
Conclusions: Our results suggest that better understanding of CYP 
expression in tumors should be useful and essential, 1) to investigate 
the mechanism of carcinogenesis, 2) to apply CYP expression as tumor 
marker, 3) to use the knowledge of CYP expression for molecular 
targeting therapy, 4) for selection of anti-cancer drug. 
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Background: Neuropilin-1 (NRP-1) is an isoform-speciﬁc receptor 
for vascular endothelial growth factor (VEGF165) and semaphorin3A. 
Its expression has been reported on a number of tumour cell lines in 
the absence of the other VEGF receptors, where it potentially mediates 
VEGF survival signals. In this study we examined the expression of 
NRP-1 in retrospective lung cancer tissue, its correlation with survival 
the mechanisms whereby neutralization of NRP-1 inhibits survival in 
NSCLC cell lines. 
Methods: A549, SK-MES1, H460 and H647 NSCLC cells were grown 
in serum depleted media (0.5%) and screened for NRP-1 expression 
using western analysis and immunocytochemistry. Cell survival / 
proliferation were determined by BrdU ELISA following treatment 
with NRP-1 neutralising antibody or recombinant human VEGF. 
Apoptosis was determined using the multi-parameter apoptosis kit and 
In-cell Analyser, and also by FACS. Gene alterations following NRP-1 
neutralisation in both A549 and SKMES-1 cells were assessed by quan-
titative PCR arrays and validated by RT-PCR. A panel of retrospective 
resected lung tumours were stained for NRP-1 expression by immuno-
histochemistry. 
Results: A549, SKMES-1 and H647 cell lines were strongly positive 
for NRP-1 expression, while NRP-1 expression was absent in H460 
cells. All three cell lines positive for NRP-1 displayed signiﬁcantly 
(p<0.05)reduced survival following treatment with NRP-1 antibody 
(1ug/ml) compared to controls (A549 36%, SKMES-1 51%, H647 
43%), while no inhibition of survival was observed on H460 cell line 
(104%). Neutralisation of NRP-1 induced apoptosis in a dose dependent 
manner, with decreased f-actin ﬁlaments and loss of mitochondrial mass 
potential. QPCR array data implicated a number of genes regulating 
these effects which were validated by RT-PCR, including downregu-
lation of bcl-2, MMP1, VEGF and integrin α4. To further examine 
these mechanisms we are preparing cell clones with silenced NRP-1 
expression using shRNA technology. The efﬁcacy of combining NRP-1 
neutralising antibody with low dose chemotherapy in currently under in-
vestigation. NRP-1 expression was observed in a variety of human lung 
cancers with different histological subtypes; however strongest expres-
sion was noted in adenocarcinoma compared to squamous cell cancer. 
Conclusions: These results implicate NRP-1 signaling as an important 
survival pathway in lung cancers. Neutralisation of NRP-1 decreased 
NSCLC survival, inducing apoptosis through mechanisms including 
downregulation of bcl-2, integrin α4 and VEGF. NRP-1 expression was 
particularly noted in lung adenocarcinoma. Combining strategies tar-
geting NRP-1 with conventional cytotoxic chemotherapy may proove 
useful as new therapeutic strategies for the treatment of NSCLC.
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Anti-angiogenic therapy inhibiting VEGFR2 signaling seems to be an 
attractive treatment of small cell lung cancer (SCLC) because SCLC 
produces those receptors. It is reported that effects of small molecules 
such as geﬁtinib, an EGFR inhibitor, depend on the status of their tar-
gets. We studied effects of ZD6474 which inhibits VEGFR2 as well as 
EGFR on human small cell lung cancer in terms of anti-angiogenesis.
We compared the effects of a VEGFR2 inhibitor, ZD6474, between 
SCLCs with and without VEGFR2. SBC-1 showed strong VEGFR2 
expression by RT-PCR and the expression was not detectable in MS-1-
L. Effects of ZD6474 on cell proliferation and VEGF production were 
studied. VEGF in culture medium was measured by ELISA. These 
human SCLC cell lines were inoculated to the nude mice (BALB/c-nu/
nu). After inoculated tumor became 2x2x2 mm, xenografts were treated 
with ZD6474, 12.5, 25 and 50 mg/kg/day, by oral administration for 
three weeks. The tumor volume was compared between that with 
ZD6474 administration and that without it. After 3-week treatment, tu-
mor specimens were pathologically evaluated using H&E and TUNEL 
staining. Tumor angiogenesis was studied by counting vessels in the 
inoculated tumor by staining vascular endothelial cells with anti-CD31 
immunostaining.
VEGF concentration in culture medium of SBC-1 and MS-1-L was 
0.44 and 0.99 ng/mL after 72 hours of culture with fresh medium with-
out ZD6474, respectively. Addition of ZD6474 did not change VEGF 
production in SBC-1, however, the VEGF production was increased 
to be 3.0 ng/mL in MS-1-L cells when 10 μM ZD6474 was added. 
ZD6474 did not signiﬁcantly inhibit SBC-1 cell growth, in contrast, 
10 μM ZD6474 signiﬁcantly stimulated the cell growth in MS-1-L 
cells. In SBC-1 xenografts, tumor volume was decreased by ZD6474 
administration in a dose-dependent manner. In MS-1-L, 12.5 mg/kg/
day ZD6474 inhibited the tumor growth, however, the tumor growth 
was stimulated when 50 mg/kg/ day ZD6474 was given. MVC in the 
inoculated tumor was decreased in SBC-1 by ZD6474 administration, 
in contrast, MVC did not signiﬁcantly change in MS-1-L by ZD6474.
We found that ZD6474 was effective against SCLC producing VEG-
FR2. However, ZD6474 stimulated SCLC growth by inducing VEGF 
production and angiogenesis in SCLC without VEGFR2 expression.
